ALPS Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

ALPS Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-294,872	Closed	-$5.77M	–	990
2018 Q3	$5.77M	Buy	294,872 +56,548	+24%	+$1.08M	0.04%	154
2018 Q2	$3.95M	Buy	238,324 +18,517	+8%	+$282K	0.03%	186
2018 Q1	$3.12M	Buy	219,807 +38,203	+21%	+$564K	0.02%	179
2017 Q4	$2.65M	Buy	181,604 +20,726	+13%	+$291K	0.02%	177
2017 Q3	$2.04M	Buy	160,878 +14,011	+10%	+$178K	0.01%	187
2017 Q2	$1.74M	Buy	146,867 +8,136	+6%	+$101K	0.01%	190
2017 Q1	$2.03M	Sell	138,731 -16,235	-10%	-$263K	0.01%	174
2016 Q4	$2.51M	Sell	154,966 -50,163	-24%	-$910K	0.02%	168
2016 Q3	$3.72M	Sell	205,129 -20,141	-9%	-$394K	0.03%	154
2016 Q2	$3.71M	Buy	225,270 +46,126	+26%	+$746K	0.03%	140
2016 Q1	$2.97M	Sell	179,144 -30,701	-15%	-$537K	0.03%	133
2015 Q4	$4.55M	Sell	209,845 -38,008	-15%	-$740K	0.04%	126
2015 Q3	$4.91M	Buy	247,853 +94,518	+62%	+$2.99M	0.05%	114
2015 Q2	$5.33M	Buy	153,335 +94,269	+160%	+$2.88M	0.05%	114
2015 Q1	$1.53M	Buy	+59,066	New	+$1.08M	0.01%	164

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ALPS Advisors's HZNP Position: Q4 2018 in Review

ALPS Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2018, closing a stake of 294,872 shares — an estimated $5.77M sold.

ALPS Advisors first reported a position in HZNP in Q1 2015 and held it in 15 quarters. The position peaked at $5.77M in Q3 2018. 239 funds tracked by Wall St. Rank hold HZNP as of Q4 2018.

ALPS Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2018 after selling out during the quarter.
ALPS Advisors sold 294,872 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2018, an estimated $5.77M.
ALPS Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 15 quarters.
ALPS Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.77M in Q3 2018.
239 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.